- Open Access
Heterogeneous matrix stiffness regulates the cancer stem-like cell phenotype in hepatocellular carcinoma
Journal of Translational Medicine volume 20, Article number: 555 (2022)
Solid tumors are stiffer than their surrounding normal tissues; however, their interior stiffness is not uniform. Under certain conditions, cancer cells can acquire stem-like phenotypes. However, it remains unclear how the heterogeneous physical microenvironment affects stemness expression in cancer cells. Here, we aimed to evaluate matrix stiffness heterogeneity in hepatocellular carcinoma (HCC) tissues and to explore the regulation effect of the tumor microenvironment on stem-like phenotypic changes through mechanical transduction.
First, we used atomic force microscopy (AFM) to evaluate the elastic modulus of HCC tissues. We then used hydrogel with adjustable stiffness to investigate the effect of matrix stiffness on the stem-like phenotype expression of HCC cells. Moreover, cells cultured on hydrogel with different stiffness were subjected to morphology, real-time PCR, western blotting, and immunofluorescence analyses to explore the mechanotransduction pathway. Finally, animal models were used to validate in vitro results.
AFM results confirmed the heterogenous matrix stiffness in HCC tissue. Cancer cells adhered to hydrogel with varying stiffness (1.10 ± 0.34 kPa, 4.47 ± 1.19 kPa, and 10.61 kPa) exhibited different cellular and cytoskeleton morphology. Higher matrix stiffness promoted the stem-like phenotype expression and reduced sorafenib-induced apoptosis. In contrast, lower stiffness induced the expression of proliferation-related protein Ki67. Moreover, mechanical signals were transmitted into cells through the integrin–yes-associated protein (YAP) pathway. Higher matrix stiffness did not affect YAP expression, however, reduced the proportion of phosphorylated YAP, promoted YAP nuclear translocation, and regulated gene transcription. Finally, application of ATN-161 (integrin inhibitor) and verteporfin (YAP inhibitor) effectively blocked the stem-like phenotype expression regulated by matrix stiffness.
Our experiments provide new insights into the interaction between matrix stiffness, cancer cell stemness, and heterogeneity, while also providing a novel HCC therapeutic strategy.
Primary liver cancer is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths, with hepatocellular carcinoma (HCC) accounting for 75–85% of cases . Although considerable progress has been made in the diagnosis and treatment of HCC over the past few decades, treatment efficacy remains unsatisfactory . Common treatment resistance and relapse are driven primarily by the inherent heterogeneity within cancer, which allows drugs to eliminate some, but not all, malignant cells .
Cancer stem cell (CSC) models have been used to explore cellular heterogeneity. CSCs, also known as tumor-initiating cells (T-ICs), are present in solid tumors and constitute a small fraction of cancer cells . CSCs generate cell heterogeneity by setting a differentiation hierarchy in tumors, resulting in a range of different cell types . Hepatic CSCs are considered responsible for the heterogeneous and hierarchical organization of HCC [6,7,8]. Under certain conditions, CSCs and non-CSCs can transform into each other; that is, terminally differentiated cells can reverse differentiation and obtain characteristics of CSCs . For example, the inflammatory tumor microenvironment (TME) promotes cancer cell dedifferentiation into CSCs, and the paracrine effects of stromal cells can also modulate the cancer stem-like phenotype .
The TME, the “soil” of cancer cells, is highly heterogeneous; previous studies have focused on the associated cellular components, including cancer-associated fibroblasts (CAFs) and immune cells [11,12,13]. As the role of the physical microenvironment in tumors has become better understood, stiffness, a commonly altered feature in solid tumors, has gained increasing attention. Stiffness is the ability of a material to resist elastic deformation under force, typically measured by the elastic modulus, E. In cancer, the extracellular matrix (ECM), a noncellular component of the TME, becomes highly dysregulated, with matrix protein deposition and excessive cross-linking causing matrix stiffening . This increased stiffness is the most notable and recognized mechanical abnormality in solid tumors . Although stiffness is postulated to regulate the stem-like phenotype of HCC cells , these associated studies treated HCC or fibrotic liver as tissues with a homogenous increase in stiffness  without considering the stiffness heterogeneity in the TME. Given the high heterogeneity of HCC, it first manifests in each patient, it then develops in different tumor nodules of the same patient, and finally in different portions of the same tumor nodules . There is reason to believe that the physical microenvironment of HCC is heterogeneous, however, few studies on this aspect have been conducted.
Mechanotransduction is the mechanism by which cells adapt to the environment by converting mechanical signals from the microenvironment into biochemical signals . Integrins are heterodimeric transmembrane receptors composed of α- and β-subunits that mediate cell adhesion and convey mechanical and chemical signals to the cell interior. Many integrin complexes can sense matrix stiffness . The yes-associated protein (YAP), a transcriptional coactivator of the Hippo pathway, has recently been shown to be a sensor and mediator of mechanical signaling in the ECM. YAP senses changes in cytoskeletal tension  and regulates gene transcription mainly by binding to TEA domain family 1–4 (TEAD 1–4) after nuclear translocation . In adult tissues, nuclear YAP is commonly found at sites where somatic stem or progenitor cells are enriched. Additionally, YAP is crucial for tissue repair in vivo and for the growth of organ-specific stem cells as organoids in vitro . Importantly, YAP is commonly overexpressed in murine and human HCC and is associated with adverse outcomes .
Here, we aimed to evaluate matrix stiffness heterogeneity in HCC tissues. Our evaluation combined the heterogeneity of HCC cells and the stiffness heterogeneity of the TME, thus, demonstrating the regulatory effect of the TME on stem-like phenotypic changes via mechanotransduction.
HCC samples from patients
Tissue samples were collected from patients with HCC (n = 3) who underwent curative resection at the General Surgery Department, First Hospital of Lanzhou University. Three different regions of the maximum cross-section of HCC tissue were randomly selected. Each sample was cut into two pieces, one of which was immediately transferred to pre-cooled (4 ℃) phosphate-buffered saline (PBS) buffer containing 1% protease inhibitor cocktail (HY-K0010, MCE), while the other was immersed in 4% paraformaldehyde (P1110, Solarbio) for subsequent analyses. This project was approved by the First Hospital of Lanzhou University Ethics Committee (Number: LDYYLL-2021-473). Informed consent was obtained from all patients in accordance with institutional guidelines.
Histology and immunohistochemistry
Paraffin-embedded tissue samples were cut into 5-μm thick sections, deparaffinized with xylene, and dehydrated using graded alcohol washes. Antigen retrieval was performed for all sections by heating in a microwave oven, and endogenous peroxidase activity was blocked with 3% H2O2 solution. After 1 h of serum blocking, anti-NANOG (sc-293121, Santa Cruz) or anti-OCT4 (sc-5279, Santa Cruz) antibodies were added to samples and incubated overnight at 4 ℃. The samples were then incubated with a secondary antibody, and then a chromogenic agent (DA1016, Solarbio) was added. In addition, human HCC tissues were stained with Sirius Red. Immunohistochemistry results were analyzed using ImageJ software, and the final results were presented using the average optical density.
Young's modulus was applied to represent the elastic modulus and characterize the strength of the stiffness. Young’s modulus was measured by atomic force microscopy (AFM) with Nanowizard III (JPK, Germany) in the force spectroscopy mode. For tissue samples, borosilicate glass beads (20 μm diameter) were attached to pyramidal cantilevers (NanoAndMore, USA) with a spring constant of 0.08 N/m. Fresh tissue samples were embedded with OCT (4583, SAKURA) and sliced into 100-μm slices using a Microtome Cryostat (Leica, CM1950). The slices were then placed on adhesive glass coverslips, placed in a 35-mm Petri dish, and approximately 2 ml of pre-cooled (4 ℃) PBS buffer containing 1% protease inhibitor cocktail (HY-K0010, MCE) was added. Measurements were performed immediately. For each sample, indentation tests were performed to generate at least 15 force curves across six 100 × 100 μm2 regions. Young’s modulus was calculated using AFM software by fitting the Hertz contact model to the acquired force curves .
HCCLM3 and Huh7 human HCC cell lines were kindly provided by the Key Laboratory of Biotherapy and Regenerative Medicine (Gansu, China). Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; C11995500BT, Gibco) supplemented with 10% fetal bovine serum (AB-FBS-1050S, ABW) and 1% penicillin–streptomycin solution (03-031-1B, BI) at 37 °C in a humidified incubator containing 5% CO2. Cells were identified using short tandem repeat DNA analysis.
Preparation of mechanically tunable polyacrylamide gel
Polyacrylamide (PA) hydrogel with tunable stiffness was prepared according to the method described by Tse and Engler . In brief, 500 μl of 0.1 M NaOH (S835850, Macklin) solution was added to round glass coverslips with a diameter of 25 mm and dried in an oven at 80 ℃. Another 500 μl of distilled H2O (dH2O) was added, dried, and repeated until a uniform NaOH coating was formed on the coverslip surface. 3-Aminopropyltriethoxysilane (A7440, Solarbio) (300 µl) was spread across each coverslip; after 5 min, the coverslips were extensively washed in dH2O and then soaked in 0.5% glutaraldehyde (G810413, Macklin) in PBS buffer for 30 min, and air dried for later use. The glass slides were then immersed in dimethyldichlorosilane (D806824, Macklin) for 5 min. Acrylamide (A800656, Macklin) and bis-acrylamide (N813086, Macklin) solutions (Table 1), 1:100 volume of AP (AR1166, Boster), and 1:1000 volume of TEMED (AR1165, Boster) were mixed. The gel mixture (25 µl) was quickly pipetted onto the slides, and inverted coverslips were carefully placed (treated side down) onto the gel droplet. The gel was allowed to polymerize for 5–10 min. The bottom glass slide was removed, and the top coverslip-gel composite was placed in a Petri dish. The mixture was rinsed twice with dH2O to remove unpolymerized acrylamide. The dH2O was removed, and 800 μl of 0.2 mg/ml sulfo-SANPAH (A35395, Pierce) solution was added to the gel surface. The reaction was carried out for 15 min under UV light. Rinsing was performed twice with 2 ml of 50 mM HEPES solution. Collagen I (354,236, Corning) HEPES solution (1 ml 0.1 mg/ml) was added and incubated overnight at 4 ℃. The cells were rinsed twice with PBS and placed under UV light for 30 min before culturing.
Cells cultured on hydrogel with different stiffness were fixed in 4% paraformaldehyde (P1110, Solarbio) for 30 min and permeabilized with 0.2% Triton X-100 (T8200, Solarbio) for 20 min. The cells were then blocked with 10% goat serum (AR1009, Boster) for 1 h and incubated with anti-Ki67 antibody (27309-1-AP, Proteintech) or anti-YAP antibody (13,584–1-AP, Proteintech) overnight at 4 ℃. Subsequently, the cells were incubated with CoraLite488-conjugated secondary antibody (SA00013-2, Proteintech) or rhodamine-conjugated secondary antibody (SA00007-2, Proteintech) for 1.5 h in the dark. F-actin was stained with rhodamine-phalloidin (CA1610, Solarbio). Nuclei were counterstained with 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI) (AR1176, Boster), and images were captured by fluorescence microscopy (Olympus, IX73). For tissue sections, after deparaffinization and dehydration, the remaining protocol was the same as that for cells.
Total RNA was extracted using TRIzol reagent (9108, Takara) and reverse-transcribed using the PrimeScript RT Reagent Kit (RR047A, Takara). Quantitative PCR was performed using TB Green premix Ex Taq (RR820A, Takara) on a Real-Time PCR Detection System (Bio-Rad, CFX96). Relative mRNA expression was analyzed and normalized to that of GAPDH. All reactions were performed in triplicate, and at least three independent experiments were performed. The primer sequences are summarized in Table 2.
Total protein was extracted using RIPA buffer (AR0102, Boster) supplemented with a protease inhibitor cocktail (HY-K0010, MCE) and phosphatase inhibitor (AR1183, Boster). The concentration of extracted proteins was measured using a BCA Protein Assay Kit (PC0020, Solarbio), and equal amounts of extracted proteins were loaded onto SDS-PAGE. The size-separated proteins were transferred to polyvinylidene fluoride (PVDF) membranes (IPVH00010, Millipore) for blotting. After blocking with 5% BSA blocking buffer (SW3015, Solarbio), membranes were incubated overnight at 4 °C with the following specific primary antibodies: anti-YAP antibody (13584-1-AP, Proteintech), anti-phosphorylated YAP antibody (Ser127) (13008 T, Cell Signaling Technology), anti-NANOG antibody (sc-293121, Santa Cruz), anti-OCT4 antibody (sc-5279, Santa Cruz), and anti-GAPDH antibody (10494-1-AP, Proteintech). Following washing, membranes were incubated for 1 h with horseradish peroxidase-conjugated secondary antibodies (SA00001-2, Proteintech). Protein expression was detected using ECL western blotting substrate (PE0010, Solarbio), and the membranes were imaged using a membrane imaging system (Clinx, ChemiScope S6).
HCC cells cultured on hydrogel with different stiffness were collected and washed twice with pre-cooled (4 ℃) PBS. A PE-conjugated anti-human CD133 antibody (394,004, Biolegend) was used for surface marker analysis. For apoptosis testing, cells were stained using an apoptosis kit (40302ES20, Yeasen), according to the manufacturer’s instructions. Flow cytometry was performed using a flow cytometer (Beckman, CytoFLEX) with software.
Subcutaneous tumorigenesis model of HCC cells mixed with hydrogel of different stiffness
Twenty-four four-week-old male BALB/c nude mice were purchased from the Gempharmatech company (Jiangsu, China). HCCLM3 cells (3 × 106) were mixed with VitroGel (TWG001, TheWell) at various concentrations. VitroGel is a xeno-free, tunable hydrogel that can be adjusted to 30–12,000 Pa by changing the hydrogel concentration with the dilution solution. The dilution ratios are listed in Table 3. The mixture was subcutaneously injected into the upper right flank of mice. Subcutaneous tumor formation was observed after 7 days. The stiff + verteporfin group was intraperitoneally injected with 50 mg/kg/day verteporfin for 7 days, and the remaining nude mice were fed normally. Our experiment conforms to the NIH Guide for Care and Use of Laboratory Animals. All animal experimental protocols were approved by the First Hospital of Lanzhou University Ethics Committee (Number: LDYYLL-2021-473).
GraphPad Prism 8 was used for statistical analyses. The experimental data were presented as the mean ± standard deviation (SD) and were analyzed using Student’s t-test. P values are represented as asterisks (*) on graphs (*P < 0.05; **P < 0.01; ***P < 0.001).
HCC tissue has heterogeneous matrix stiffness
To assess the stiffness heterogeneity in HCC tissues, we collected surgical specimens from patients with HCC and randomly selected three tissue samples at the maximum cross-section of the specimens, which were labeled as A, B, and C groups (Fig. 1A). Sirius Red staining was used to evaluate collagen deposition, and AFM was used to determine the local stiffness (Young’s modulus) of the tissue. Sirius Red staining showed that the collagen content in different parts of the tumor tissue differed significantly. Group A had a small amount of collagen, and group B had a medium amount of collagen, whereas group C contained a large number of disordered collagen fibers (Fig. 1B). Further, with AFM (Fig. 1C, D) detection, the Young’s modulus of the tissues was found to be significantly different: group A, E = 1051.61 ± 434.27 Pa; group B, E = 4540.35 ± 2666.98 Pa; group C, E = 9307.37 ± 4989.91 Pa (Fig. 1E). Additionally, the increase in stiffness was consistent with the amount of collagen in the tissue. Similar to the results of previous studies, tissue stiffness largely depended on the amount of collagen deposition and cross-linking [25, 26]. Furthermore, the difference in Young’s modulus was not only reflected in the different sampling sites but also at the same sampling site (Fig. 1F).
HCC cells exhibit different cellular and cytoskeletal morphology on hydrogel with varying stiffness
Next, we used collagen I-coated PA hydrogel with adjustable stiffness to simulate the differential stiffness in the tissues (Fig. 2A). PA hydrogel exhibits good biocompatibility and stability. Based on the AFM analysis of HCC tissues, the average stiffness of the different regions (A: 1051.61 Pa, B: 4540.35 Pa, and C: 9307.37 Pa) was used to design the hydrogel. We adjusted the stiffness of the hydrogel by changing the ratio of acrylamide and bis-acrylamide (according to the ratio in the previous literature ), and the final stiffness values of the hydrogel were 1.10 ± 0.34 kPa, 4.47 ± 1.19 kPa, and 10.61 kPa (Table 1), represented as soft, medium, and stiff, respectively. The HCC cell lines, HCCLM3 and Huh7, exhibited different cell morphologies on hydrogel with different stiffness. That is, the cell morphology was relatively round on soft hydrogel, while on medium and stiff hydrogel, the cell morphology became gradually elongated and extended. The analysis showed that cells on medium and stiff hydrogel had greater surface areas (Fig. 2B, C). Actin filaments play an important role in mechanosensing . After cytoskeleton staining with rhodamine-labeled phalloidin, we observed that cells on medium and stiff hydrogel had clearer stress fibers and actin filament networks compared with those on the soft hydrogel (Fig. 2D).
HCC stem-like cell phenotype, drug resistance, and proliferative ability in response to different stiffness
HCCLM3 and Huh7 cells exhibited different stem-like phenotypes on hydrogel with different stiffness. CSC maintenance is regulated by various transcription factors, including NANOG and OCT4 . Differences were detected in the mRNA and protein levels of NANOG and OCT4 based on the hydrogel, from soft to stiff. Compared with the soft hydrogel, the NANOG and OCT4 expression increased in cells on the stiff hydrogel (Fig. 3A, B, C). CD133 is a transmembrane glycoprotein expressed in adult stem cells. Ma et al.  first reported CD133 as a marker of hepatic CSCs. Flow cytometry analysis showed that the proportion of CD133-positive cells exhibited the same trend as that of NANOG and OCT4 expression, gradually increasing from soft to stiff hydrogel (Fig. 3D, Additional file 1: Fig. S1A).
Considering that the stemness of cancer cells is closely related to drug resistance, we treated cells cultured on hydrogel with different stiffness with 10 μM sorafenib for 24 h and then carried out apoptotic cell analysis. The proportion of apoptotic cells on the soft hydrogel was the largest, whereas that on the stiff hydrogel was the smallest (Fig. 4A, Additional file 1: Fig. S1B). Immunofluorescence analysis of proliferation-related protein Ki67 showed that the fluorescence intensity of cells on soft hydrogel was significantly higher than that on medium and stiff hydrogel (Fig. 4B, C).
Increased matrix stiffness regulates cancer stem-like cell phenotype via the integrin–YAP pathway
YAP is a transcriptional coactivator that shuttles from the cytoplasm to the nucleus through dephosphorylation and binds to TEAD and other transcription factors to promote gene expression. YAP is also a transducer of cellular structures, including polarity, morphology, and cytoskeletal structure, and it can reprogram non-stem cancer cells into cells with CSC attributes [30, 31]. To explore the role of YAP in stiffness and cancer cell stemness, PCR analysis was performed. No significant difference in the mRNA expression of YAP was observed when cells were cultured on hydrogel with different stiffness. However, CTGF and ANKRD expression, which are typical downstream genes of YAP, increased significantly with an increase in stiffness (Fig. 5A).
Considering YAP function, we examined its subcellular localization. Immunofluorescence results indicate that YAP aggregation in the nucleus increased with increasing stiffness (Fig. 5B, C). Subsequent WB results confirmed that there was no significant difference in the total amount of YAP among the three groups. However, the phosphorylated YAP content decreased with increasing stiffness, indicating that the number of activated YAP increased (Fig. 6A, B).
Verteporfin is a YAP inhibitor that inhibits the binding of YAP to TEAD, thereby inhibiting its transcriptional activity. Hence, HCCLM3 cells cultured on hydrogel with different stiffness were treated with verteporfin (1 μg/ml) for 24 h, and the mRNA expression of NANOG and OCT4 was analyzed. NANOG and OCT4 mRNA expression remained higher in cells on stiff hydrogel, however, the differences were notably smaller than those without the inhibitor. Moreover, the ratio of NANOG expression on stiff hydrogel and soft hydrogel decreased from approximately 6.7-fold to 1.3-fold, while that of OCT4 expression decreased from approximately 2.0-fold to 1.6-fold.
Integrins are cell surface proteins that sense the mechanical characteristics of the microenvironment . ATN-161 (Ac-PHSCN-NH2) is a small peptide antagonist of several integrins, including integrin-α5β1. Hence, HCCLM3 cells cultured on hydrogel with different stiffness were treated with ATN-161 (10 μmol/ml) for 24 h and the resulting mRNA expression was analyzed. No significant differences were observed in NANOG nor OCT4 mRNA expression among the three groups. However, the NANOG expression was lower in the medium and stiff groups compared with the soft group (Fig. 6C).
These experiments were then repeated in Huh7 cells and the differences in the expressions of NANOG and OCT4 mRNA following verteporfin treatment were similar to that in HCCLM3 cells. Moreover, no significant difference was detected in NANOG expression following treatment with ATN-161; whereas OCT4 expression was inhibited to a certain extent (Additional file 2: Fig. S2).
To verify the effectiveness of the inhibitors, ATN-161 and verteporfin were added to HCCLM3 and Huh7 cells cultured on stiff hydrogel for 24 h. WB analyses suggested that there was no significant difference in YAP abundance between the stiff and stiff + ATN-161 groups, whereas it was significantly reduced in the stiff + verteporfin group. Moreover, the abundance of pYAP in the stiff group was lower than that in the stiff + ATN-161 group, and was lower yet in the stiff + verteporfin group (Fig. 6D).
Matrix stiffness regulates the stem-like phenotype of HCC cells in vivo
Finally, we performed subcutaneous tumorigenesis in nude mice to explore whether the cells could reproduce the in vitro experimental results. HCCLM3 cells were mixed with hydrogel of adjustable stiffness and injected subcutaneously into nude mice. After injection, the soft, medium, and stiff groups were fed normal diets. In the stiff + verteporfin (stiff + VP) group, verteporfin (50 mg/kg) was continuously injected intraperitoneally from day 8 to 14 (Fig. 7A). Nude mice were euthanized after 14 days, and subcutaneous tumor tissues were collected. Tumor volumes decreased significantly with an increase in matrix stiffness. However, there were no significant differences between the stiff and stiff + VP groups (Fig. 7B, C). Immunohistochemical staining revealed that the abundances of NANOG and OCT4 proteins increased significantly with increased matrix stiffness. Immunofluorescence results showed that the translocation of YAP into the nucleus increased with increasing matrix stiffness. Moreover, in the soft and medium groups, cytoskeleton morphology was not observed, whereas in the stiff and stiff + VP groups, the cytoskeleton morphology was clear (Fig. 7D, E).
Here, we described the heterogeneity of matrix stiffness within HCC tissues and how stiffness affects HCC cells via the integrin–YAP pathway to regulate the expression of stem-like phenotypes (Fig. 8).
HCC is a highly heterogeneous tissue. CSCs have been proposed as one of the determining factors that contribute to intratumoral heterogeneity. Stemness traits are acquired via genetic modifications and/or interactions with the TME . According to our results, there is also heterogeneity in the stiffness of the HCC microenvironment, which can directly regulate the expression of stem-like phenotypes via cellular mechanotransduction. According to our analysis of stemness-related HCC markers (NANOG, OCT4 and CD133), OCT4 expression in HCCLM3 cells did not differ significantly between those cultured on medium and high stiffness, which is reflected in both mRNA and protein levels. We postulated that different cells exhibit a range of adaptation to stiffness. That is, there was no significant difference in the induction of stemness expression by stiffness within a certain range.
YAP expression level did not increase with increasing matrix stiffness, while that of its downstream genes, ANKRD and CTGF, increased. We suggest that YAP might not elicit effects via increased expression but rather through activation. Subsequent WB and immunofluorescence experiments confirmed this hypothesis. A stiffer matrix can promote YAP aggregation in the nucleus by dephosphorylation to increase transcription of NANOG and OCT4. Moreover, application of YAP inhibitor partially prevented the induction of stemness expression by stiff substrates both in vivo and in vitro. Because YAP is not the only factor that regulates stem-like expression, there are other cellular pathways related to stemness.
Integrins can transduce mechanical signals into cells; therefore, we hypothesized that they are upstream regulators of YAP. To test this hypothesis, we treated HCC cells with an integrin inhibitor and found that the expression of stemness-related markers and active YAP was decreased. Moreover, the expression of NANOG on stiff hydrogel was lower than that on soft hydrogel. This may have been caused by the specific integrin inhibitor that was used, ATN-161, as it acts on several integrin isoforms, thereby causing extensive inhibition of the downstream mechanical pathways.
Matrix stiffness can additionally affect drug resistance in HCC cells. Following sorafenib treatment, HCC cells cultured on a stiffer matrix exhibited lowered apoptosis levels, which were positively correlated with the expression of stem-like phenotypes. Matrix stiffening inherently constitutes a mechanical barrier against drug delivery  and can also enhance the resistance of the cell itself, thus, complicating chemotherapy. Recently, drugs targeting matrix stiffness have proven effective in experiments and are gradually being applied in clinical settings . However, matrix stiffness can also affect HCC cell proliferation. Here, HCC cells had a stronger proliferative ability when cultured on a soft matrix both in vivo and in vitro. CSC has the ability to self-renew, but this does not equate to greater proliferative ability. Although there is no direct experimental evidence that CSCs undergo cell cycle arrest; in fact, they have been shown to incorporate DNA labels and are therefore often described as slow-cycling cells . Moreover, the drug resistance and responsibility for recurrence make CSCs overlap with dormant cancer cells (non-proliferating cancer cells undergoing G0-G1 cell cycle arrest) . This could lead to another problem: if sorafenib is administered in combination with other treatments that reduce matrix stiffness, the softened matrix will increase the proliferative capacity of HCC cells, thus reducing the therapeutic efficacy. Therefore, drugs that reduce matrix stiffness might not be the best choice for HCC treatments. Indeed, many drugs targeting matrix stiffness have been designed to target CAFs, degrade ECM, or reduce cross-linking ; however, their application faces some challenges. For instance, the non-specificity of surface markers of CAFs leads to inaccurate targeting, the role of CAF subsets in tumor promotion and inhibition is not fully understood as well . Moreover, degradation of the ECM may remove the obstacle of cancer invasion . According to our in vivo results, tumor-bearing mice did not show significantly altered tumor size when treated with a YAP inhibitor suggesting that treatments targeting the cellular mechanotransduction pathway may be more effective.
Contrary to our experimental results, previous studies have indicated that the expression of stem-like phenotypes in HCC cells was higher when cultured on soft substrates . This may be due to the application of hydrogel with different stiffness and reactivities with HCC cell lines, which requires further exploration. Meanwhile, in another study, higher matrix stiffness was found to trigger epithelial-mesenchymal transition (EMT) of HCC cells  and promote the formation of a pre-metastatic niche . In fact, several studies have shown an association between EMT and the acquisition of stem-like phenotypes ; our results are consistent with these experiments.
Here, we aimed to establish a relationship between the heterogeneity of the cancer mechanical microenvironment and the expression of stem-like phenotypes. We observed that HCC cells grown on hydrogel with different stiffness expressed different degrees of stem-like phenotypes. However, the heterogeneity of cancer cells appears during the hierarchical differentiation of CSCs, and we cannot dynamically observe the process of mechanical factors regulating stemness expression owing to the lack of cancer cell markers at different differentiation levels. Therefore, it is challenging to maintain cells at one stage of differentiation to enable analyses such as drug sensitivity. Additionally, our animal experiments used mechanically tunable polysaccharide hydrogel, which differs from previous studies that used components, such as Matrigel or collagen to simulate matrix stiffness. Collagen and other components regulate the mechanical properties via adapting the concentration. Previous experiments have confirmed that the concentration of collagen has a certain impact on the biological behavior of cells , as well as other physical properties (such as cell-binding sites, pore size, porosity, and degradability) change . Therefore, these biological materials cannot exclude these effects. Moreover, owing to the high heterogeneity of the TME, simulating it in its entirety in vitro is challenging and will require continued advancement of the associated technology.
Our experimental results show that the stiffness of the HCC microenvironment is heterogeneous, and the effect of matrix stiffness on cancer cells affects stem-like expression, consequentially forming tiny mechanical niches, leading to the heterogeneity of cells and poor therapeutic effects. In this process, the integrin-YAP pathway conducts mechanical signals to regulate cell function. Hence, targeting cell mechanotransduction pathways may be a new strategy for eradicating drug resistance.
Availability of data and materials
The datasets analyzed in this study are available from the corresponding author on reasonable request.
Cancer stem cell
Atomic force microscopy
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Cheng Z, Li X, Ding J. Characteristics of liver cancer stem cells and clinical correlations. Cancer Lett. 2016;379:230–8.
Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018;18:669–80.
Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139–52.
Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–9.
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68.
Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;21:283–96.
Lee J-S, Heo J, Libbrecht L, Chu I-S, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410–6.
Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA. 2011;108:7950–5.
Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017;16:41.
Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99.
Wing JB, Tanaka A, Sakaguchi S. Human FOXP3 Regulatory T Cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50:302–16.
Wu S-Y, Fu T, Jiang Y-Z, Shao Z-M. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19:120.
Cox TR. The matrix in cancer. Nat Rev Cancer. 2021;21:217–38.
Nia HT, Munn LL, Jain RK. Physical traits of cancer. Science (New York, NY). 2020;370:6516.
Schrader J, Gordon-Walker TT, Aucott RL, van Deemter M, Quaas A, Walsh S, Benten D, Forbes SJ, Wells RG, Iredale JP. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology (Baltimore, MD). 2011;53:1192–205.
Masuzaki R, Tateishi R, Yoshida H, Sato T, Ohki T, Goto T, Yoshida H, Sato S, Sugioka Y, Ikeda H, et al. Assessing liver tumor stiffness by transient elastography. Hep Intl. 2007;1:394–7.
Panciera T, Azzolin L, Cordenonsi M, Piccolo S. Mechanobiology of YAP and TAZ in physiology and disease. Nat Rev Mol Cell Biol. 2017;18:758–70.
Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35:347–67.
Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011;474:179–83.
Totaro A, Panciera T, Piccolo S. YAP/TAZ upstream signals and downstream responses. Nat Cell Biol. 2018;20:888–99.
Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan S-T, Luk JM, Wigler M, Hannon GJ, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125:1253–67.
Harris AR, Charras GT. Experimental validation of atomic force microscopy-based cell elasticity measurements. Nanotechnology. 2011;22: 345102.
Tse JR, Engler AJ. Preparation of hydrogel substrates with tunable mechanical properties. Curr Protoc Cell Biol. 2010. https://doi.org/10.1002/0471143030.cb1016s47.
Plodinec M, Loparic M, Monnier CA, Obermann EC, Zanetti-Dallenbach R, Oertle P, Hyotyla JT, Aebi U, Bentires-Alj M, Lim RYH, Schoenenberger C-A. The nanomechanical signature of breast cancer. Nat Nanotechnol. 2012;7:757–65.
Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SFT, Csiszar K, Giaccia A, Weninger W, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139:891–906.
Hayakawa K, Tatsumi H, Sokabe M. Mechano-sensing by actin filaments and focal adhesion proteins. Communicative Integrative Biol. 2012;5:572–7.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.
Ma S, Chan K-W, Hu L, Lee TK-W, Wo JY-H, Ng IO-L, Zheng B-J, Guan X-Y. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542–56.
Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;29:783–803.
Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94:1287–312.
Nicolas-Boluda A, Silva AKA, Fournel S, Gazeau F. Physical oncology: new targets for nanomedicine. Biomaterials. 2018;150:87–99.
Lampi MC, Reinhart-King CA. Targeting extracellular matrix stiffness to attenuate disease: from molecular mechanisms to clinical trials. Sci Transl Med. 2018;10:0475.
Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20:398–411.
Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018;17:1147–55.
Dong Y, Zheng Q, Wang Z, Lin X, You Y, Wu S, Wang Y, Hu C, Xie X, Chen J, et al. Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis. J Hematol Oncol. 2019;12:112.
Wu S, Zheng Q, Xing X, Dong Y, Wang Y, You Y, Chen R, Hu C, Chen J, Gao D, et al. Matrix stiffness-upregulated LOXL2 promotes fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation. J Exp Clin Cancer Res. 2018;37:99.
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69–84.
Kuczek DE, Larsen AMH, Thorseth M-L, Carretta M, Kalvisa A, Siersbæk MS, Simões AMC, Roslind A, Engelholm LH, Noessner E, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019;7:68.
Park S-N, Park J-C, Kim HO, Song MJ, Suh H. Characterization of porous collagen/hyaluronic acid scaffold modified by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide cross-linking. Biomaterials. 2002;23:1205–12.
We would like to thank Editage (www.editage.cn) for English language editing, and Biorender (www.biorender.com) for the assistance in creating figures.
This work was supported by the National Natural Science Foundation of China (82060119) and Fundamental Research Funds of Lanzhou University (lzujbky-2021-kb37).
Ethics approval and consent to participate
All animal experimental protocols were approved by the First Hospital of Lanzhou University Ethics Committee (Number: LDYYLL-2021–473).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1: Fig. S1.
(A) CD133-positive Huh7 cells cultured on hydrogel with different stiffness were estimated by flow cytometry. (B) Apoptotic Huh7 cells on hydrogel with different stiffness treated with sorafenib.
Additional file 2
: Fig. S2. Relative mRNA expression levels of NANOG and OCT4 in Huh7 cells on hydrogel with different stiffness treated with verteporfin or ATN-161.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Wei, J., Yao, J., Yang, C. et al. Heterogeneous matrix stiffness regulates the cancer stem-like cell phenotype in hepatocellular carcinoma. J Transl Med 20, 555 (2022). https://doi.org/10.1186/s12967-022-03778-w
- Matrix stiffness
- Cancer cell stemness
- Hepatocellular carcinoma
- Yes-associated protein